PHATHOM PHARMACEUTICALS, INC. Operating Lease Cost
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Operating Lease Cost of $51.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2020-03-19
- PHATHOM PHARMACEUTICALS, INC. operating lease, cost for fiscal 2019 was $51.00K.
| Period end | Operating Lease, Cost 12 month |
|---|---|
| 2019-12-31 | $51.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |